Arbidol hydrochloride is licensed in Russia and China mainly for treatment of influenza infection and other respiratory viral infections. It is both a direct-acting antiviral and host-targeting agent with broad-spectrum activity interacting with membrane and viral or cellular proteins, exerting inhibition ability involved in viral entry, viral fusion, replication, assembly, budding, and stimulation of host immune responses. 

Uses and related research

In February 2020, Li Lanjuan, a famous Chinese epidemiologist, claimed that arbidol hydrochloride and darunavir in preliminary tests could inhibit the replication of new coronavirus in vitro. She proposed using arbidol and darunavir for treating pneumonia patients suffering from SARS-CoV-2 infection. Prominently, novel coronavirus infected patients in Wuhan and Shanghai receiving arbidol showed significant signs of improvement in pneumonia. Phase IV clinical trials involving arbidol/arbidol hydrochloride alone or in combination with interferon atomization, oseltamivir or Lopinavir/Ritonavir for treatment of SARS-CoV-2 viral pneumonia are under investigation (NCT04255017, NCT04260594, NCT04254874).

Arbidol hydrochloride tablet is a non-nucleoside broad-spectrum antiviral drug with immune-enhancing effect. Abidor is pharmacodynamic in vitro against a variety of coronaviruses.This is a randomized, open, multicenter clinical study of pneumonic subjects diagnosed with 2019-ncov infection. The main objective was to compare the viral negative conversion rate in the first week after the subjects were randomized to arbidol plus basic treatment.

In this study, 380 eligible patients with pneumonia diagnosed with 2019-ncov infection were randomly assigned to one of two treatment groups at a 1:1 ratio.

patients will receive one of two treatment regimens: 

A .Abidor tablets + basic treatment 

B. basic treatment Arbidol tablets: take 2 tablets/time, 3 times/day for 14-20 days Basic treatment :The basic treatment used by the investigator was based on the condition of the patient.